Background
The current HIV pandemic is heavily skewed against women. HIV infection in women accounts for 450% of new HIV infections in adults worldwide. Once infected, emerging data points to differences in HIV pathogenesis and anti-HIV immune responses in women in comparison to men (Gandhi et al., 2002; Meier et al., 2009; Sterling et al., 2005; Weinberg et al., 2011) . Female sex hormones, at least in part, may contribute to gender-based differences in HIV acquisition and pathogenesis. Particularly, female sex hormones regulate immune responses both systemically and in the female genital tract by impacting homing of HIV-susceptible cells to mucosal tissue, regulating cytokine production and antimicrobial peptides induction, and influencing lymphocyte responses (Fahey et al., 1999; Fahey and Wira, 2002; Fung et al., 2013; Kaushic et al., 1998; Lu et al., 2002; Quayle et al., 1998; Rodriguez-Garcia et al., 2013) . This intricate balance between host factors under female sex hormone regulation and HIV is likely to impact HIV transmission and pathogenesis in women.
Some clinical data suggest that lower estrogen level (e.g. progesterone dominant stage) is correlated with higher rate of HIV infection and higher plasma viral load. Specifically, during the periovulatroy stage of the menstrual cycle, when estrogen dominates, HIV plasma viral load is decreased (Greenblatt et al., 2000; Hanna, 1999; Money et al., 2003) . Further, HIV productive infection of human cervical explant tissue predominately occurs in tissue obtained from women in their secretory phase of the menstrual cycle, a stage where progesterone dominates and counteracts estrogen effects (Saba et al., In press ). Lastly, women on progesterone-based injectable hormonal contraceptives are more likely to become HIV infected and to transmit the virus to their male partners (Heffron et al., 2012) . Taken together, these clinical observations suggest that estrogen dominance may be linked to lower susceptibility of cells to HIV infection.
17β-Estradiol, the most potent estrogen found in humans, exerts an anti-viral effect for a number of viruses. It inhibits hepatitis C virus (HCV) infection at multiple steps including attachment, entry, replication, and post-replication (Hayashida et al., 2010; Murakami et al., 2013) . It also inhibits hepatitis B virus (HBV) transcription (Wang et al., 2012) , limits herpes simplex virus (HSV) primary infection and reactivation (Gillgrass et al., 2010; Vicetti Miguel et al., 2010) , and inhibits rubella virus replication (Roehrig et al., 1979) . 17β-Estradiol, on the other hand, promotes the replication of adenovirus type 12 (James et al., 1992) .
The signal transduction cascade of estrogen is complex and can be engaged by multiple pathways. Canonical estrogen signaling involves the activation of its nuclear receptors, estrogen receptor α (ERα) or estrogen receptor β (ERβ), which in turn bind to estrogen responsive elements (ERE) located near or within gene promoters to regulate the transcriptional activity of cognate target genes (Marino et al., 2006) . Estrogen also regulates gene expression via noncanonical signaling whereby (Marino et al., 2006) estrogen receptors bind to other transcriptional factors such as Sp1 or Ap-1, leading to either their stabilization of recruitment of transcriptional co-regulators, which in turn bind to their cognate promoters to regulate gene expression. Also, estrogen can bind to either its nuclear receptors or other receptors to initiate second messenger signaling leading to physiologic effects. These signal transduction pathways include ERK/MAPK, p38/MAPK, or PI3K/AKT, to name a few (Marino et al., 2006) . Interestingly, many of the reported 17β-estradiol reported anti-viral effects are mediated by ERα and not ERβ (Hayashida et al., 2010; Murakami et al., 2013; Wang et al., 2012; Gillgrass et al., 2010; Vicetti Miguel et al., 2010; Roehrig et al., 1979) .
β-Catenin signaling represses HIV replication in multiple targets, including PBMCs at the level of transcription Kumar et al., 2008; Li et al., 2011) . β-Catenin is a transcriptional co-regulator and is the central mediator of the canonical Wnt/β-catenin signaling pathway (Al-Harthi, 2012) . β-catenin binds to members of the TCF/LEF family of transcription factors (TCF1, TCF3, TCF-4, and LEF) to modulate hundreds of genes, including those that regulate cell proliferation and survival. β-catenin expression is regulated at the protein level by a multiprotein destruction complex (GSK-3β, APC, Axin, and casein kinase 1). This multi-protein complex leads to the phosphorylation, ubiquitination, and proteasomal degradation of β-catenin. When this destruction complex is destabilized, β-catenin is hypophosphorylated and translocates to the nucleus where it binds to TCF/ LEF transcription factors, tethering on their cognate DNA binding sites to regulate genes such as CyclinD, C-Myc, Matrix metalloproteinase 7 and 9, and Axin, to name a few (Al-Harthi, 2012) .
At least four TCF-4 binding sites have been identified within the HIV promoter at −143 to −136 nt; −336 to −329 nt; +66 to +73 nt; and +186 to +195 nt from the transcription initiation site . While all sites have 470% homology to the TCF-4 binding sequence, the −143 site has 100% homology to the TCF-4 core (5′-(A/T)(A/T)CAAAG-3′) and is present in approximately one-third of 500 HIV LTR sequences reported in the Los Alamos gene bank . TCF-4 binds at a higher affinity at −143 than at any other site . Further, β-catenin is tethered on the HIV LTR at the nt−143 site and knockdown of either TCF-4 or β-catenin enhances HIV transcription Narasipura et al., 2012) . Dual knock down of β-catenin and TCF4 does not further enhance HIV LTR activity, indicating that these factors work together to repress HIV transcription.
Given that HIV replication is regulated by a complex interplay between virus and host factors and some epidemiologic data linking an estrogen dominant state to lower plasma viral load and infection rate, we directly assessed the role of estrogen (17β-estradiol) on HIV replication in peripheral blood mononuclear cells (PBMCs). We demonstrate that estrogen through engaging ERα leads to association between ERα and β-catenin that tethers on the HIV LTR at −143 nt from the transcription initiation site to repress HIV transcription. These findings provide the first direct association between ERα and β-catenin on the HIV LTR, impacting HIV transcription. Further, the mechanism revealed here may contribute to some clinical observations linking lower HIV load under an estrogen dominant state (Asin et al., 2008; Greenblatt et al., 2000; Money et al., 2003) . Most importantly, these studies add to a growing list of viruses (HCV, HBV,HSV, rubella) that are inhibited by ER through ERα engagment (Gillgrass et al., 2010; Hayashida et 
17β-Estradiol inhibits HIV replication in PBMCs
PBMCs were stimulated with anti-CD3/CD28 prior to HIV Bal infection then treated with 17β-estradiol (0-3 nM) or AZT (1 μM). At day seven post infection, HIV replication was monitored by conventional HIV core antigen (p24) ELISA. We demonstrate that 17β-estradiol at 1.5 and 3 nM inhibited HIV replication by approximately 40% (Fig. 1a) . 17β-Estradiol at these two doses also inhibited HIV strain (IIIB), a T-tropic/CXCR-4 utilizing strain (Fig. 1b) . None of these 17β-estradiol doses (0.001-3 nM) were cytotoxic to PBMCs, as evaluated by the MTS assay (data not shown).
Robust expression of ER α in PBMCs
To determine which estrogen receptor (ERα or ERβ) is involved in 17β-estradiol-mediated inhibition of HIV replication, we evaluated ERα and ERβ expression in PBMCs. Using an antibody that recognizes both ERα and ERβ we show that ER expression is 480% in all lymphocyte subsets and that T cell activation through anti-CD3/CD28 stimulation did not significantly increase ER expression in T cells ( Fig. 2a and b) . Using an antibody that is specific for either ERα or ERβ, we demonstrate robust expression of ERα in PBMCs and low level of ERβ expression (Fig. 2c ). 17β-Estradiol treatment of PBMCs at doses that inhibited HIV replication (1.5 and 3 nM) did not significantly induce ERα or ERβ expression (Fig. 2c ).
17β-Estradiol inhibition of HIV replication is dependent on ERα and is at the level of HIV transcription
To determine the role of ERα or ERβ in estrogen mediated inhibition of HIV, we used an ERα agonist and an ERβ antagonist. We were unable to use an ERα antagonists in PBMCs because ERα antagonists are highly context dependent and in some cases they function as agonist instead of antagonist. For example, 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (known as MPP) depending on the cell type can be an ERα agonist or antagonist (Shang and Brown, 2002) . In PBMCs, ER agonists functioned as antagonist (data not shown). For this reason, we used an ERα agonist (4,4′,4″-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, PPT) to assess if engaging ERα leads to HIV inhibition. PPT inhibited HIV replication by approximately 40%, a magnitude that was similar to that mediated by 17β-estradiol (Fig. 3a) . The ERβ antagonist (2-Phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol, PHTPP) did not abrogate the ability of 17β-estradiol to inhibit HIV replication in PBMCs (Fig. 3b) . Together, these findings indicate that the mechanism by which 17β-estradiol mediates HIV inhibition is dependent on ERα and is independent of ERβ. To determine the step of the HIV life cycle whereby 17β-estradiol may exert its inhibitory effect, PBMCs were infected with HIV Bal and HIV reverse transcription, integration, and transcription were assessed by conventional real time PCR-based assays. 17β-estradiol inhibited HIV transcription by approximately 40% and had no effect on HIV reverse transcription or integration ( Fig. 4c-e ).
17β-Estradiol induces β-catenin signaling
Given that 17β-estradiol inhibited HIV transcription and we defined β-catenin through its interaction with TCF-4 as a potent repressor of HIV transcription Kumar et al., 2008; Narasipura et al., 2012) , we evaluated the relationship between 17β-estradiol and β-catenin signaling. 17β-Estradiol induced active β-catenin expression in PBMCs as evaluated by Western blot (Fig. 5a ) and intracellular staining for β-catenin (Fig. 5b) . 17β-estradiol also induced classical target genes of β-catenin-mediated transcription such as axin-2, c-Myc, and cyclinD1 (Fig. 5c ). Inhibition of TCF-4 through transfection with a dominant negative TCF-4 construct abrogated the ability of 17β-estradiol to induce axin-2 mRNA, indicating that 17β-estradiol-mediated induction of axin-2 is β-catenin specific (Fig. 5d) . Collectively, these data demonstrate that 17β-estradiol activates β-catenin signaling. This is the first study, to our knowledge, to demonstrate 17β-estradiol activation of β-catenin signaling in PBMCs.
17β-Estradiol induces the stable association of β-catenin and ERα
We assessed the interaction between ERα and β-catenin in PBMCs by immunoprecipitation (IP) and western blot (WB). While β-catenin was pulled down by ERα IP, the level of β-catenin pulled down by ERα IP was significantly higher when the cells were treated with 17β-estradiol (Fig. 6a) . These data indicate that 17β-estradiol potentiates the interaction between ERα and β-catenin, which maybe driven by higher level of β-catenin in response to 17β-estradiol or stabilization of β-catenin in presence of 17β-estradiol to promote its interaction with ERα.
Inhibiting β-catenin abrogates the ability of 17β-estradiol to inhibit HIV replication XAV and IWR-1 Endo are two small molecules described to inhibit β-catenin signaling by stabilizing axin-2, a scaffolding protein that is part of the β-catenin destruction complex (Huang (Fig. 6b) . Collectively, these data indicate that the mechanism by which 17β-estradiol mediates HIV inhibition is both ERα dependent and β-catenin dependent.
ERα, β-catenin, and TCF-4 associate with the HIV LTR at −143 nt site from transcription initiation site
We evaluated whether ERα, β-catenin, and TCF-4 are associated with the HIV LTR to repress transcription. β-catenin does not bind DNA directly rather acts as a transcription co-factor by binding to TCF/LEF transcription factors. Recently several TCF-4 binding sites were identified on the HIV LTR . One in particular, at −143 from +1 transcription start site (−143 to −136 nt) is where TCF-4 and β-catenin associate with the nuclear matrix protein SMAR1 to pull the HIV DNA towards the nuclear matrix and away from RNA pol II transcriptional machinery . We assessed whether ERα tethers at −143 by chromatin immunoprecipitation. Jurkat cells were transfected with ERα plasmid and WT-LTR or an LTR deleted in −143 from the +1 start site (LTR Δ −143). The chromatin was pulled down using IgG or ERα antibody and the DNA amplified for HIV LTR. We show that deletion of −143 dramatically diminished the association of ERα with the HIV LTR at the −143 site (Fig. 7a) . Further, β-catenin and TCF-4 were confirmed to associate with the HIV LTR at −143 (Fig. 7b) . Collectively, these data demonstrate that ERα, β-catenin, and TCF-4 all associate at −143 nt site of the HIV LTR. Discussion 17β-Estradiol levels greatly fluctuate during the menstrual cycle, reaching peak levels in the preovulatory phase (4690 to o2,120 pmol/l) and declining in the luteal phase (4300 to o710 pmol/l) (Harlow and Ephross, 1995) . The level of 17β-estradiol is also highly variable among women and within the same woman from one menstrual cycle to the next. For this reason, we evaluated a wide dose of 17β-estradiol effects on HIV replication in PBMCs. We show here that 17β-estradiol at a physiologic dose reported during the preovulatory phase of women of reproductive age (1.5 nM equivalent to 1500 pmol/l) (Harlow and Ephross, 1995) inhibits HIV replication in PBMCs at the level of transcription by engaging the association between β-catenin, TCF-4 and ERα at −143 nt site of the HIV LTR. The −143 nt site of the HIV LTR is of a particular importance because it was recently demonstrated to be associated with β-catenin/TCF-4/ and SMAR protein to inhibit POLII docking and repress HIV transcription . Based on our data we propose that under low level of 17β-estradiol minimal interaction between ERα and β-catenin occurs, which does not protect β-catenin from degradation. However, under a 17β-estradiol dominant state, the interaction between ERα and β-catenin is induced leading to stabilization of β-catenin, its subsequent translocation into the nucleus, and its association with TCF-4 to repress HIV LTR activity. Although the LTR has estrogen responsive elements (EREs) at 343 and −231 nt from transcription initiation site, those sites are not relevant to the association between β-catenin and ERα on the HIV LTR, as deletion of −143 nt site alone abrogated the tethering of β-catenin, TCF-4, and ERα on the HIV LTR.
Our findings suggest that fluctuations in 17β-estradiol levels during the menstrual cycle and across the reproductive stage of women may impact HIV load and in turn HIV pathogenesis and transmission. Indeed, some studies reported that HIV genital shedding is highest during menses (low estrogen) and declines during the follicular stage (high estrogen). Other studies found that the menstrual cycle leads to a decline in plasma HIV load in the follicular to mid-luteal stage (high estrogen) without impacting HIV vaginal shedding (Greenblatt et al., 2000; Hanna, 1999; Reichelderfer et al., 2000 Reichelderfer et al., , 2002 Villanueva et al., 2002) . Mid-secretory levels of estrogen and progesterone, together, were also found to inhibit HIV replication in vitro in PBMCs (Asin et al., 2008) . However, depending on the estrogen dose, there was either no effect or negligible effect on HIV replication in this study (Asin et al., 2008) . This may be reflection of several experimental factors, the most important of which is the use of charcoal stripping in these studies. In our study, the ability of 17β-estradiol to inhibit HIV replication in PBMCs was conducted without charcoal stripping. Historically, charcoal stripping of FBS was performed to remove endogenous steroid hormones, especially in breast and cervical cancer cell lines that are highly enriched in steroid production. However, emerging evidence indicates that charcoal stripping eliminates other metabolites essential for cellular health (Cao et al., 2009 ). In our experience, charcoal stripping of FBS compromises the survival of PBMCs (data not shown). For this reason and because untreated cultures serve as background for endogenous 17β-estradiol/steroids levels, we have elected not to use charcoal stripping in our cultures and showed that 17β-estradiol at preovulatroy doses inhibits HIV replication and revealed the mechanism by which it does so.
Cross-talk between 17β-estradiol and Wnt/β-catenin has been described in mouse and human epithelial cells (Hou et al., 2004 Kouzmenko et al., 2004 . We provide the first evidence in human PBMCs that 17β-estradiol induce ERα and β-catenin interaction to potentiate HIV repression. In human and mouse uterine epithelial cells, 17β-estradiol induces β-catenin gene expression and activates a number of Wnt proteins, including Wnt4, Wnt5a, and frizzled receptor 2 (Hou et al., 2004) . Further, ERα and β-catenin in human colon and breast cancer cells precipitate within the same immune complexes (Kouzmenko et al., 2004) , demonstrating that ERα and β-catenin are physically associated with each other. Exogenous 17β-estradiol further enhances this physical interaction of ERα and β-catenin. The result of ERα and β-catenin physical association is a reciprocal regulation of cognate target genes (Kouzmenko et al., 2004) .
ERα represses the replication of a number of viruses, including HCV, HBV, HSV, and rubella (Gillgrass et al., 2010; Hayashida et al., 2010; Murakami et al., 2013; Roehrig et al., 1979; Vicetti Miguel et al., 2010; Wang et al., 2012) . We show here that ERα also inhibits HIV replication. These findings indicate that ERα engages direct anti-viral pathways to limit replication of some viruses, which may mediate gender-specific differences in susceptibility to virus infection and/or spread. In the case of HCV, women are more likely to clear HCV in acute stage than men and female sex hormones have been suggested as a potential factor for better clearance (Bakr et al., 2006) . Some studies have also alluded to women having a 2-6 fold lower plasma viral load than men during acute and chronic HIV infection (Delmas et al., 1997; Gandhi et al., 2002; Lemly et al., 2009; Meditz et al., 2011; Sterling et al., 1999 Sterling et al., , 2001 , although additional studies are needed to assess the direct contribution of female sex hormones on HIV replication and progression in the clinical setting suggest.
Materials and methods

Ethics statement
This study was approved by Rush Institutional Review Board (09040706-IRB01) and participants' written consent was provided. 
Reagents
AZT, 17β-estradiol, PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol), PPT (4,4′,4′′-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol), anti-total β-catenin antibody, amino acids 768-781 (cat. C2206), and anti-GAPDH antibody (cat. G9545) purchased from Sigma Aldrich (St. Louis, MO, USA). Anti-active β-catenin antibody clone 3C196 purchased from US Biologicals (San Antonio, TX, USA). Anti-ERα antibody clone 62A3 purchased from Cell Signaling (Boston, MA). Anti-ERβ antibody clone 14C8 purchased from Abcam (Cambridge, MA, USA). XAV 939 and IWR-1-endo purchased from Tocris Bioscience (Bristol, United Kingdom).
Isolation and treatment of PBMCs
PBMCs were isolated from venous blood of healthy women of reproductive age and not on hormone contraceptives using lymphocyte separation medium (Lonza Biotech, Allendale, NJ, USA) and density centrifugation. The cells were suspended in phenol red free-RPMI complete medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin, 1% streptomycin, and 20 U/ml IL-2. PBMCs were left unstimulated or stimulated with 1 μg/ml each of anti-CD3/CD28 antibodies (BD Biosciences, Franklin Lake, NJ, USA) for 24 h at 37 1C under 5% CO 2 . Fig. 5 . 17β-estradiol induces β-catenin signaling. PBMCs were stimulated and treated with 17β-estradiol (1.5 nM) for three days. Western blot and densitometry quantification for active β-catenin measured by Western blot is shown in (a). Flow cytometric analysis of active β-catenin expression in CD4+ and CD8+ T cells is shown in (b). Level of downstream targets of Wnt/β-catenin pathway (axin-2, c-Myc, cyclin D-1) post 17β estradiol treatment performed by real time RT-PCR is shown in (c). GAPDH was used as endogenous control and data shown as fold change relative to untreated cells. In (d) PBMCs were stimulated with antiCD3/CD28 for 48 h and nucleofected with a dominant negative plasmid for TCF-4 (dnTCF4) or backbone vector (pcDNA). Post nucleofection the cells were treated with 17β-estradiol (1.5 nM) for three days and axin-2 and c-myc mRNA level was evaluated by real-time RT-PCR. GAPDH was used as endogenous control. Data is representative of a minimum of three experiments and analyzed by Student T-test; n p o0.05.
Immunofluorescence staining and flow cytometric analysis
Up to nine-color flow cytometric analyses were performed using a FACSCalibur cytometer with CellQuest (BD) and LSR-II cytometer with Diva software (BD). Aqua Live/Dead staining was used. The following antibodies from BD Biosciences were used for cell surface staining as per instructions: For T cells subsets, CD3-alexafluor 700, CD14-pacific blue, CD8-phycoerythrin-cyanine (PerCP-Cy) 5.5, CD4-allophycocyanin (APC), CD19 APC-H7; for dendritic cell subsets, CD3-PerCP-Cy7, CD123-phycoerythrin (PE), HLA-Dr PerCP, CD14-pacific blue, CD11c-APC, CD56/CD16-alexfluor 700 and CD19/CD20-APC-H7. Proper isotypes were purchased from same vendor for primary stain. Intracellular flow cytometry staining was performed using CytoPerm/fix and CytoWash reagents, according to recommendations of the supplier (BD Biosciences). For ERs staining, 10 μl of a FITC-conjugated rabbit monoclonal antibody that recognizes both ERα and ERβ (clone SP1, Abcam, Cambridge, MA, USA) was used. For active β-catenin, 200 μl of 0.05 μg dilution in PBS of mouse anti-human active β-catenin un-conjugated antibody (clone 3C196, US Biological, Marbelhead, MA) was used followed by 1 μl of a secondary antimouse F(ab′)2 FITC-conjugated antibody at 2 mg/ml. The cells were subsequently washed and fixed with 2% paraformaldahyde.
Cell viability, HIV infection, and p24 assay
Cell viability was assessed by standard MTS assay (Promega, Madison, WI). HIV-1 Bal or HIV IIIB at 2 ng HIV p24/10 6 cells was added to anti-CD3/CD28 stimulated PBMCs and incubated for 4-6 h at 37 1C under 5% CO 2 . Cells were then washed with PBS three times to remove un-bound virus, suspended in phenol red free-RPMI complete medium with 20 units/ml IL-2, treated as indicated per experimental condition, and plated in 96 well U-bottom plate at 200,000 cells/ 200 μl volume of the media in quadruplicates for 7 days at 37 1C, 5% CO 2 . HIV p24 assay was performed using p24 ELISA kit (SAICFrederick, MD) according to the manufacturer's protocol.
Western blot and immunoprecipitation (IP)
The cells were lysed using RIPA buffer (Sigma) with 10% protease inhibitors and protein content measured by Pierce BCA assay (Thermo Fisher, Barrington, IL). Western blot was performed as described , using anti-active β-catenin antibody at 1:8000, anti-total β-catenin antibody at 1:8000, anti-ERα at 1:1000, anti ERβ at 1:1000, and/or anti-GAPDH at 1:30,000. Secondary antibodies included goat anti-mouse HRP (Pierce) at 1:50,000 and goat anti-rabbit HRP (Cell Signaling) at 1:60,000 for GAPDH. Densitometries were measured by ImageJ software. For IP, cell lysate was pre-cleared with 25 μl of protein A/G magnetic Fig. 6 . 17β-estradiol-mediated inhibition of HIV replication is β-catenin-dependent PBMCs were stimulated with anti-CD3/CD28 antibodies for 48 h then left untreated or treated with 17β-estradiol (1.5 nM). At day three, the cells were harvested, lysed, and the protein immunoprecipitated (IP) using ERα antibodies or IgG control then probed with β-catenin (a). In (b) the ability of small molecule inhibitors of β-catenin to abrogate 17β-estradiol-mediated inhibition of HIV replication is shown. Specifically, PBMCs were stimulated with anti-CD3/CD28, infected with HIV Bal , left untreated or treated with 17β-estradiol at 1.5 nM with or without small molecule inhibitors of β-catenin (XAV at 1 mM and IWR-1-endo at 2.5 mM) or treated with 1 μM AZT. HIV p24 was measured by ELISA on day seven post-infection. HIV p24 levels form XAV and IWR-1-endo treatments alone, without 17β-estradiol, was not statistically different than untreated cultures. Data is representative of a minimum of three experiments and analyzed by Student T-test; n po 0.05, NS indicate not significant (p 40.05). beads (Thermo Scientific), cross-linked with specific antibodies using Protein A/G MagSepharose and SpinTrap Buffer Kit (GE Healthcare, Piscataway, NJ) as outlined by manufacturer. Denatured proteins were then resolved on a 12% SDS gel. IgG controls were run in parallel.
RNA isolation and real time PCR
Total RNA was isolated from PBMCs using Trizol (Life Technologies, Grand Island, NY). Complimentary DNA synthesis was performed using qScript cDNA Supermix (Quanta BioSciences, Gaithersburg, MD). Real-time PCR was performed employing SsoFast EvaGreen Supermix with low ROX (BioRad, Hercules, CA) in a 7500 real time PCR system (Applied Biosystems, Carlsbad, CA) to quantify target genes. Reaction conditions were: 95 1C for 10 min followed by 40 cycles of 95 1C for 15 s, 60 1C for 1 min and 95 1C for 30 s. A melting curve stage was included to make sure that single specific products were amplified devoid of non-specific products or primer-dimers. Fold change in product expression was calculated by relative quantification using the comparative C T method with GAPDH as endogenous control. The following primers were used to amplify Wnt/β-catenin pathway target genes: c-Myc, F-5′-ACGTC TCCACACATCAGCACAACT and R-5′-TGACACTGTCCAACTTGACCCTCT; CyclinD1, F-5′-TCATGGCTGAAGTCACCTGGT and R-5′-TCCACTGGA-TGGTTTGTCACTGGA; Axin2, F-5′-ACAACAGCATTGTCTCCAAGCAGC and R-5′-GCGCCTGGTCAAACATGATGGAAT and GAPDH, F-5′-TGA-CTTCAACAGCGACACCCACT and R-5′-ACCACCCTGTTGCTGTAGCC AAAT.
Analysis of HIV reverse transcription, integration and transcription
Stimulated PBMCs were infected with HIV Bal and treated or untreated as described above. For HIV reverse transcription analysis, infected cells were harvested at 24 h, genomic DNA isolated using DNeasy blood and tissue kit (Qiagen, Valencia, CA), quantitative real time PCR was performed to quantify HIV LTR using F-5′-TCAAGTGAGTGCCCGGTT and R-5′-AGCTCCGGTTTCT CTTTCGCT primers. For HIV integration analysis, infected cells were harvested at 72 h AND Alu-PCR was performed as described (Brussel and Sonigo, 2003) . A minus Taq and a minus template controls were included throughout. For HIV transcription analysis, at 72 h post infection, cDNA was subjected to real time PCR using the following primers to amplify HIV transcripts: Rev, F-5′-TCCT TGGCACTTATCTGGGACGAT and R-5′-TCCCAGAAGTTCCACAATCC-TCGT and Env, F-5′-ACGAGGATTGTGGAACTTCTGGGA and R-5′-TGGCATTGAGCAAGCTAACAGCAC. GADPH was used as endogenous control.
Nucleofection and transfection
Stimulated PBMCs were transfected with dominant negative (dn) TCF-4 plasmid (Addgene; Cambridge, MA) and pcDNA backbone (Invitrogen; Carlsbad, CA) using Amaxa T cell Nucleofection kit and Amaxa Program T-23 (Lonza, Walkersville, MA). Jurkat cells were transfected with 0.5 μg ERα expression plasmid (pEGFP-C1-ER alpha, Addgene, Cambridge, MA), 0.5 μg of either the WT-LTR or Δ-143-LTR previously described using Lipofectamine 2000 (Invitrogen).
Chromatin immunoprecipitation (ChIP) and quantitative real-time PCR
At 48 h post-transfection, chromatin immunoprecipitation (ChIP) was performed using EMD Millipore EZ Magna ChIPA/G (Temecula, CA) according to manufacturer's protocol with antibodies for total β-catenin (Sigma) and ERα (Thermo). An appropriate IgG (CellSignaling) control antibody was also included. Real time PCR was performed to quantify HIV LTR DNA using above mentioned LTR primers in a 7500 real time PCR system employing SsoFast EvaGreen Supermix with low ROX. Reaction conditions were: 95 1C for 10 min followed by 40 cycles of 95 1C for 15 s, 60 1C for 1 min and 95 1C for 30 s. A melting curve stage was included to ensure amplification of a single product. Change in binding was calculated by relative quantification using the comparative threshold cycle (C T ) method. Results were reported as fold change relative to IgG control (ΔC T ¼C T Target −C T IgG control ; fold change relative to IgG control¼2 − Δ Ct ).
Statistics
When the data was distributed normally, ANOVA and post-hoc tests were used. When the data was not normally distributed, nonparametric analysis was performed. All tests assumed a twosided significance level of 0.05. GraphPad Instat 3 software (San Diego, CA) was used for data analysis. 
